drugset / Trial / NCT02610088
Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide
RandomizedParallel-groupTriple-blindTreatment
Summary
The investigators set up a clinical trial to compare effect of dapagliflozin, a sodium glucose co-transporter 2 inhibitor, with gliclazide on vascular function in patients with type 2 diabetes
Timeline
- Start
- 2015-11
- Primary completion
- 2018-07
- Completion
- 2018-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | Oral |
| Comparator | Gliclazide | Small molecule | 30 mg | Oral |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |